Tarsus Pharmaceuticals (TARS) Total Current Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Total Current Liabilities history runs 8 years deep, the most recent figure standing at $143.5 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 66.27% year-over-year to $143.5 million; the TTM figure through Mar 2026 stood at $143.5 million (up 66.27% YoY), while the FY2025 annual figure was $135.7 million, up 68.33% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $143.5 million, up from $135.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $143.5 million in Q1 2026, with the low at $11.7 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $42.5 million (2024), against an average of $56.2 million.
• The sharpest annual moves came in 2023 and 2024: Total Current Liabilities increased 5.11% in 2023, then surged 249.28% in 2024.
• Tarsus Pharmaceuticals' Total Current Liabilities stood at $15.4 million in 2022, then jumped by 139.39% to $36.9 million in 2023, then surged by 118.25% to $80.6 million in 2024, then soared by 68.33% to $135.7 million in 2025, then increased by 5.76% to $143.5 million in 2026.
• Business Quant data shows TARS's Total Current Liabilities at $143.5 million in Q1 2026, $135.7 million in Q4 2025, and $117.0 million in Q3 2025.